Cover Image
Market Research Report

Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023

Published by KuicK Research Product code 564392
Published Content info 190 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
Published: October 10, 2017 Content info: 190 Pages
Description

“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer janus kinase inhibitor market. As per report findings, janus kinase inhibitors have emerged as one of the new potential candidate and growth frontier for the various stake holders involved in the research and development of cancer drugs and therapies. At present there is only one janus kinase inhibitors based drug commercially available in the market and 27 drugs are in the various clinical development phases. Most of the drugs are in Preclinical phase (13 Drugs) followed by the Phase-II ( 4 Drugs) clinical trials.

“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” Highlights:

  • Mechanism of Action of JAK/STAT Inhibitors
  • Global Cancer JAK/STAT Inhibitor Market Outlook
  • Global JAK/STAT Inhibitor Market Opportunity: US$ 4 Billion
  • Global JAK/STAT Inhibitor in Pipeline: 27 Drugs
  • Global Cancer JAK/STAT Inhibitor Therapy Price Analysis
  • Global Cancer JAK/STAT Inhibitor Market Dynamics
  • Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company & Phase
  • Marketed Cancer Janus Kinase Inhibitors Clinical Insight
  • Comparative Price Analysis of JAK/STAT Inhibitors & Conventional Cancer Therapies

The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.

JAK/STAT inhibitor being the latest invention in the field of targeted therapies is considered as the best available therapy for cancer by many scientific researchers. JAK/STAT inhibitors target the process involved in the production of the damaged DNA which is playing the major role in developing cancerous cells. The available JAK/STAT inhibitors are highly focused on treating the rare hematological malignancies like myelofibrosis, polycythemia Vera and primary thrombocythemia. However, the continuous efforts of the research community has led to the identification of the role of JAK/STAT pathway in a wide range of tumors including solid tumors like lung cancer, pancreatic cancer, prostate cancer, breast cancer, colorectal cancer, ovarian cancer, gastrointestinal cancers etc.

The global revenue collection from currently available JAK/STAT inhibitor drug; Ruxolitinib, has been very impressive since its approval. Although the drug is approved for treating rare hematological malignancies but incidence rate of these cancers has been found to be increasing in the past five years. Furthermore, the lack of effective treatment for such cancers and increased survival rates of the patients after getting a treatment with Ruxolitinib has aided the commercial success of Ruxolitinib.

More than 5 JAK/STAT inhibitors are expected to enter the cancer therapeutic market in the next decade. The development of JAK/STAT inhibitors has been so impressive and rapid in the past five years that a great economic success of this class of drugs is expected in the nearby future. Additionally, huge commercial success of the JAK inhibitor Ruxolitinib for myeloproliferative disorders has further accelerated the development of more JAK/STAT inhibitors. Advancements in research and technology will aid the development of JAK/STAT inhibitors. The development of more JAK/STAT inhibitors will not only provide benefits to the cancer therapeutic market but will also provide a better life to the patients suffering from cancers.

Past success of JAK/STAT inhibitors has provided an overview of its future market. The clinical success of JAK inhibitor, Ruxolitinib has gained adequate popularity among the patients and the physicians. Due to this reason, the demand of JAK/STAT inhibitors is highly increased. Furthermore, the popularity of Ruxolitinib will aid the market success of other JAK/STAT inhibitory drugs which are going to be licensed very soon.

Table of Contents

Table of Contents

1. Prologue to JAK/STAT Pathway

  • 1.1. Overview
  • 1.2. Categorization of JAK/STAT Inhibitors in Cancer Therapeutics

2. Role of JAK/STAT Pathway in Tumor Formation

3. JAK/STAT Inhibitors: Modern Therapeutics for Effective Cancer Management

4. Understanding the Targets for Inhibition: An Insight into JAK & STAT Proteins

  • 4.1. Structure & Significance
    • 4.1.1. Janus Kinases: A Novel Cytokine Receptor
    • 4.1.2. STAT Proteins: The Signal Generators for Transcription
  • 4.2. Importance of Modulation of JAK/STAT in a Healthy Cell

5. Mechanism of Action of JAK/STAT Inhibitors

6. Identification of Active Target in Tumor Cells for JAK/STAT Inhibition

  • 6.1. Cell Based Assays
  • 6.2. Biochemical Assays

7. Need & Superiority of JAK/STAT Inhibitors: Its Importance in Modern Cancer Therapy

8. JAK/STAT Inhibitors in Cancer Therapy

  • 8.1. Hematological Malignancies
    • 8.1.1. Myelofibrosis
    • 8.1.2. Acute Lymphoblastic Leukemia
    • 8.1.3. Polycythemia Vera
    • 8.1.4. Primary thrombocythemia
  • 8.2. Solid Tumors
    • 8.2.1. Lung Cancer
    • 8.2.2. Ovarian Cancer
    • 8.2.3. Breast Cancer
    • 8.2.4. Pancreatic Cancer
    • 8.2.5. Hepatocellular Carcinoma
    • 8.2.6. Colorectal cancer
    • 8.2.7. Head & Neck Squamous Cell Carcinoma
    • 8.2.8. Prostate Cancer
    • 8.2.9. Glioblastoma
    • 8.2.10. Other Solid Tumors

9. Cancer JAK/STAT Inhibitor Drugs

  • 9.1. Approved Drugs
    • 9.1.1. Ruxolitinib
  • 9.2. Promising Candidates in the Clinical Pipeline
    • 9.2.1. Momelotinib
    • 9.2.2. Lestaurtinib
    • 9.2.3. Pacritinib

10. Global Cancer JAK/STAT Inhibitor Market Outlook

  • 10.1. Current Scenario
  • 10.2. Clinical Pipeline Overview

11. Global Cancer JAK/STAT Inhibitor Therapy Price Analysis

  • 11.1. Analyzing the Cost of Available JAK/STAT Inhibitor
  • 11.2. Comparative Price Analysis of JAK/STAT Inhibitors and Best Available Therapy
  • 11.3. Comparative Price Analysis of JAK/STAT Inhibitors & Conventional Cancer Therapies
  • 11.4. Comparative Price Analysis of JAK/STAT Inhibitors & Newly Approved Anti-Cancer Therapeutics

12. Global Cancer JAK/STAT Inhibitor Market Dynamics

  • 12.1. Favorable Factors for Cancer JAK/STAT Inhibitors Market
    • 12.1.1. Elevation in Disease Burden
    • 12.1.2. Unmet Medical Need
    • 12.1.3. Advancement in Technology
    • 12.1.4. Strong Clinical Pipeline
    • 12.1.5. Orphan Drug Status to JAK/STAT Inhibitors
    • 12.1.6. Commercial Success of Ruxolitinib
  • 12.2. Market challenges for Cancer JAK/STAT Inhibitors
    • 12.2.1. Scientific Limitations and the Number of Side Effects
    • 12.2.2. Clinical Hold on Pacritinib
    • 12.2.3. Tedious approval process

13. Global Cancer JAK/STAT Inhibitor Market Future Outlook

14. Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company & Phase

  • 14.1. Research
  • 14.2. Preclinical
  • 14.3. Phase-I
  • 14.4. Phase-I/II
  • 14.5. Phase-II
  • 14.6. Phase-III
  • 14.7. Preregistration

15. Marketed Cancer Janus Kinase Inhibitors Clinical Insight by Company

  • 15.1. Ruxolitinib (Jakafi & Jakavi)

16. Suspended Cancer Janus Kinase Inhibitors in Clinical Pipeline by Company & Phase

  • 16.1. No Development Reported
  • 16.2. Discontinued

17. Competitive Landscape

  • 17.1. Abbott Laboratories
  • 17.2. Asana Biosciences
  • 17.3. Astra Zeneca
  • 17.4. Celon Pharmaceuticals
  • 17.5. Dynamic Pharma
  • 17.6. Eli Lilly
  • 17.7. Gilead Sciences
  • 17.8. Hanmi Pharmaceuticals
  • 17.9. Incyte
  • 17.10. Kyowa Hakko
  • 17.11. Moleculin
  • 17.12. Pfizer
  • 17.13. PIQUR Therapeutics
  • 17.14. Portola Pharmaceuticals
  • 17.15. S*BIO

List of Figures

  • Figure 1-1: Conventional Approaches for Treating Cancer
  • Figure 1-2: Major Limitations of Conventional Cancer Therapies
  • Figure 1-3: Modern Approach in Cancer Therapy
  • Figure 1-4: Major Types of Cancer Treatment Modalities
  • Figure 1-5: Categorization of JAK Inhibitors in Targeted Therapies
  • Figure 3-1: Advanced Approaches for the Development of JAK/STAT Inhibitors
  • Figure 4-1: Architecture of the Structure of Janus Kinase
  • Figure 4-2: Cis Mode of Activation of Janus Kinase
  • Figure 4-3: Trans Mode of Activation of Janus Kinase
  • Figure 4-4: Architecture of the Structure of STAT Proteins
  • Figure 4-5: Activation of STAT Proteins
  • Figure 4-6: Natural Inhibitors of JAK/STAT Signaling Pathway
  • Figure 5-1: JAK/STAT Signaling Pathway in Normal Human Cell
  • Figure 5-2: JAK/STAT Pathway in Hematological Cancers
  • Figure 5-3: Mechanism of Action of JAK inhibitors
  • Figure 6-1: Technologies Used For Diagnosing JAK/STAT Pathway in Tumor Cells
  • Figure 7-1: Advanced Features of JAK/STAT Inhibitors in Cancer Therapy
  • Figure 8-1: JAK/STAT Mutations in Hematological Malignancies
  • Figure 9-1: Target & Effects of Ruxolitinib
  • Figure 9-2: Impact of Ruxolitinib on Change in Mean Spleen Size
  • Figure 10-1: Global Prevalence - Myelofibrosis Patients (Numbers), 2015-17
  • Figure 10-2: Global Prevalence - Polycythemia Vera Patients (Numbers), 2015-17
  • Figure 10-3 Global Prevalence - Primary Thrombocythemia Patients (Numbers), 2015-17
  • Figure 10-4 : Global- Ruxolitinib Revenue for Myelofibrosis (US$ Million), 2015-2017
  • Figure 10-5: Global - Ruxolitinib Revenue for Polycythemia Vera (US$ Million), 2015-2017
  • Figure 10-6: Global- Ruxolitinib Revenue for Primary Thrombocythemia (US$ Million), 2015-2017
  • Figure 10-7: Global- Ruxolitinib Revenue by Hematological Malignancies (%), 2016
  • Figure 10-8: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 10-9: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 10-10: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 10-11: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 11-1: Ruxolitinib - Average Per Tablet & Packet Cost Analysis (US$)
  • Figure 11-2: Ruxolitinib - Average & Lifetime Treatment Cost Analysis (US$)
  • Figure 11-3: Global- Average Price of Ruxolitinib Treatment (US$/Month), 2015-2017
  • Figure 11-4: Survival Rate of Myelofibrosis Patients Undergoing Ruxolitinib Treatment v/s Best Available Therapy
  • Figure 11-5: Global - Average Lifetime Expenditure of Myelofibrosis Patient (US$)
  • Figure 11-6: Global - Average Lifetime Drug & Resource Cost (US$)
  • Figure 11-7: Global - Average Cost of Complete Treatment of Myelofibrosis Patient (US$)
  • Figure 11-8: Quality Adjusted Life Years for Ruxolitinib & Best Available Therapy for Myelofibrosis
  • Figure 11-9: Average Cost of JAK/STAT Inhibitors & Conventional Therapies for Cancer (US$/Month)
  • Figure 11-10: Complete Treatment Cost of JAK/STAT Inhibitors & Monoclonal Antibody Drug (US$)
  • Figure 11-11: Treatment Cost of JAK/STAT Inhibitors & CAR-T Cell Therapy for Cancer (US$)
  • Figure 11-12: Treatment Cost of JAK/STAT Inhibitors & Other Small Molecule Cancer Drugs (US$)
  • Figure 12-1: Global - Cancer JAK/STAT Inhibitor Market Drivers
  • Figure 12-2: Global - Challenges for Cancer JAK/STAT Inhibitors Market
  • Figure 13-1: Global- Cancer JAK/STAT Inhibitors Market Opportunity (US$ Billion), 2018-2023

List of Tables

  • Table 2-1: JAK Mutations in Cancers
  • Table 2-2: STAT Mutations in Cancers
  • Table 11-1: Ruxolitinib Price Analysis
Back to Top